Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Legislation & Advocacy

Annual Meeting Advocacy Recap

Will Harvey, MD  |  December 2, 2015

Advocacy was front and center at the 2015 ACR/ARHP Annual Meeting, and in case you missed something, Will Harvey, MD, provides a summary here…

U.S. Public Health Funding on the Decline

Lisa Rapaport  |  November 20, 2015

(Reuters Health)—U.S. public health funding, which covers such things as disease prevention, cancer screenings, contraceptives and vaccines, has been steadily falling in recent years and is expected to keep going down, a recent study projects. Real, inflation-adjusted public health expenditures surged from $39 per capita in 1960 to $281 per capita in 2008, then fell…

U.S. Doctor Group Calls for Ban on Drug Advertising to Consumers

Susan Kelly  |  November 19, 2015

(Reuters)—The American Medical Association on Tuesday called for a ban on advertising prescription drugs and medical devices directly to consumers, saying the ads drive patients to demand expensive treatments over less costly ones that are also effective. The influential doctors’ group said the new policy reflects physicians’ concerns that marketing spending on a proliferation of…

Advocate for Rheumatology with the ACR

From the College  |  November 18, 2015

Your voice is an essential part of the ACR’s advocacy efforts, and our new Legislative Action Center makes contacting your legislator easier than ever before…

Obama Nominee to Lead FDA Defends Drug Industry Ties

Toni Clarke  |  November 17, 2015

(Reuters)—President Barack Obama’s nominee to head the U.S. Food and Drug Administration defended his ties to the pharmaceutical industry on Tuesday during a Senate committee hearing that included questions on soaring drug prices. Presidential candidate Bernie Sanders was among the Democrats who grilled Dr. Robert Califf (64), who joined the FDA in January as a…

Signatures to Be Filed for California Drug Price Referendum

Sharon Bernstein  |  October 30, 2015

SACRAMENTO, Calif. (Reuters)—Backers of a referendum aimed at reducing the cost of prescription drugs in California said Wednesday that they had gathered more than enough signatures to place their measure on the November 2016 ballot in the most populous U.S. state. The measure by the AIDS Healthcare Foundation would require the state to pay no…

Specialized Health Care May Be Lacking under Obamacare Plans

Andrew M. Seaman  |  October 29, 2015

(Reuters Health)—Some health insurance plans sold on the Affordable Care Act‘s federal marketplace may not provide reasonable access to medical specialists, new research suggests. Under the act, also known as Obamacare, the federal marketplace offers subsidized private health insurance to consumers in states that didn’t establish their own health insurance exchanges. About one in seven…

Ethics Forum: Personal Ethics Questions Surrounding RheumPAC Donations

Matthew L. Mundwiler, MD, & Robert H. Shmerling, MD  |  October 14, 2015

Imagine you’ve just heard a compelling presentation urging all ACR members to contribute to RheumPAC, the ACR’s political action committee. RheumPAC’s mission is to support politicians who support issues important to rheumatologists. You are impressed by the role RheumPAC has played in a number of issues you support. Just as you’re writing a check, you…

Why Rheumatologists Should Join the AMA

Gary Bryant, MD  |  October 14, 2015

Editor’s note: Welcome to the first installment of Experiences in Advocacy, a special series authored by ACR members detailing personal experiences in advocacy. We need rheumatologists to join the American Medical Association (AMA). Here’s why, and how to do it. Having participated in your delegation for over a decade, I have seen major improvements in…

Unwelcome News about Medicare’s Rising Drug Plan Costs

Mark Miller  |  October 9, 2015

CHICAGO (Reuters)—Seniors have received some unpleasant news in their mailboxes in recent weeks: premiums for many Medicare prescription drug insurance plans will rise at double-digit rates next year. Premiums for the ten most popular Medicare Part D prescription drug plans (PDPs) will rise an average of 8 percent next year—the fastest clip in five years,…

  • « Previous Page
  • 1
  • …
  • 64
  • 65
  • 66
  • 67
  • 68
  • …
  • 94
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences